BeijingSeptember 13, 2022/ PR Newswire /-- Biopharmaceutical high-tech company Nuocheng Jianhua (SEHK: 09969) announced today that it has received a notice of approval for Clinical trial approval issued by the State Drug Administration, and the company's independently developed BCL2 inhibitor ICP-248 has been approved to conduct clinical trials, becoming the company's fifth clinical innovation in the field of hematoma and the company's 13th innovative drug to enter clinical practice.
ICP-248 is a novel oral highly selective BCL2 inhibitor, which aims to treat malignant hematological tumors such as non-Hodgkin's lymphoma (NHL) and acute lymphoblastic leukemia (ALL) alone or in combination with other drugs such as BTK inhibitors. BCL2 is an important part of the apoptotic pathway and is overexpressed in many hematological malignancies. ICP-248 can activate endogenous mitochondrial apoptosis pathway, which leads to rapid apoptosis of cancer cells and plays an anti-tumor effect.
Dr. Cui Jiansong, co-founder, chairman and CEO of Nuocheng Jianhua, said: "ICP-248 will further strengthen our pipeline strength in the field of hematoma. We have developed a number of drugs that cover important targets for different mechanisms of hematological tumors, such as BTK, CD19, CD20xCD3, BCL2 and Emur3 ligases to address unmet medical needs."
About Nuocheng Jianhua
Nuocheng Jianhua (SEHK: 09969) is a commercial biomedical high-tech company specializing in the development of new drugs in the treatment of malignant tumors and autoimmune diseases. suitable for the treatment of lymphoma, solid tumors and autoimmune diseases. A number of new drug products are in the stage of commercialization, clinical and preclinical research and development. The company has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong and the United States.
Nuocheng Jianhua forward-looking statement
This press release contains the disclosure of some forward-looking statements. All statements, other than statements of facts, may be regarded as forward-looking statements, that is, statements about actions, events or developments that we or our management intend, expect, plan, believe or expect to occur or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future developments and other relevant factors. This forward-looking statement does not guarantee future performance, actual results, developments and business decisions that may not be consistent with the forward-looking statements. Our forward-looking statements are also subject to a number of risks and uncertainties, which may affect our short-term and long-term performance.
Contact person | |
media | Investors |
Lu Chunhua | |
86-10-66609879 | 86-10-66609999 |
Chunhua.lu@innocarepharma.com | Ir@innocarepharma.com |